{"nct_id":"NCT03529084","title":"Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations","status":"WITHDRAWN","status_verified_date":"2019-11","start_date":"2018-07-24","start_date_type":"ESTIMATED","primary_completion_date":"2020-08-13","primary_completion_date_type":"ESTIMATED","completion_date":"2024-06-03","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["NVS"]}